Keyphrases
Crohn's Disease
100%
Inflammatory Bowel Disease
99%
Ulcerative Colitis
95%
Vedolizumab
62%
Clinical Remission
41%
Confidence Interval
40%
Endoscopic Remission
38%
Systematic Meta-analysis
32%
Clinical Trials
26%
Infliximab
24%
Meta-analysis
23%
Ustekinumab
19%
Endoscopic Improvement
17%
Placebo
16%
Remission
16%
Odds Ratio
16%
Adalimumab
15%
Tumor Necrosis Factor Antagonist
14%
Ulcerative Colitis Patient
13%
Clinical Response
13%
Endoscopic Healing
13%
Rectal Bleeding
13%
Gut Microbiome
12%
Remission Rate
12%
Patient-reported Outcomes
12%
Endoscopy
11%
Biologic Therapy
11%
Induction Therapy
11%
Histological Remission
11%
Hospitalization
11%
Hyperbaric Oxygen Therapy
11%
Corticosteroids
10%
Serious Infection
10%
Comparative Efficacy
10%
Simple Endoscopic Score for Crohn's Disease
10%
Disease Activity
10%
Comparative Effectiveness
10%
Stool Frequency
10%
Acute Severe Ulcerative Colitis
9%
Nave
9%
Tofacitinib
9%
Colectomy
9%
Randomized Trial
9%
Hazard Ratio
8%
Randomized Controlled Trial
8%
Placebo Response Rate
8%
Low Risk
8%
Severe Ulcerative Colitis
8%
Moderate to Severe
8%
Clinical Outcomes
8%
Medicine and Dentistry
Ulcerative Colitis
92%
Crohn's Disease
76%
Inflammatory Bowel Disease
70%
Vedolizumab
51%
Patient with Ulcerative Colitis
29%
Clinical Trial
27%
Diseases
26%
Systematic Review
26%
Patient with Inflammatory Bowel Disease
24%
Post-Hoc Analysis
22%
Biological Product
21%
Meta-Analysis
19%
Patient with Crohn's Disease
19%
Infliximab
17%
Endoscopy
17%
Tumor Necrosis Factor
17%
Odds Ratio
16%
Biological Marker
15%
Disease Activity
15%
Combination Therapy
15%
Patient-Reported Outcome
13%
Rectal Bleeding
13%
Ustekinumab
12%
Adalimumab
12%
Placebo
11%
Spontaneous Remission
11%
Biological Therapy
10%
Cohort Analysis
10%
Hyperbaric Medicine
9%
Hazard Ratio
8%
Adverse Event
8%
Mesalazine
8%
Placebo Effect
8%
Maintenance Therapy
8%
Gut Microbiome
8%
Randomized Controlled Trial
7%
Ulcer
7%
Colectomy
7%
Retrospective Cohort Study
7%
Dysplasia
7%
Faecal Calprotectin
7%
Tofacitinib
7%
Nonalcoholic Fatty Liver
7%
Health Care Cost
7%
Systematic Review with Meta-Analysis
6%
Logistic Regression Analysis
6%
Fibrosis
6%
Infection
6%
Stricture
6%
Colorectal Carcinoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ulcerative Colitis
85%
Crohn's Disease
81%
Remission
76%
Inflammatory Bowel Disease
62%
Vedolizumab
42%
Clinical Trial
24%
Placebo
21%
Tumor Necrosis Factor
20%
Diseases
20%
Biological Product
19%
Infliximab
17%
Ustekinumab
15%
Combination Therapy
14%
Disease Activity
12%
Infection
12%
Adverse Event
12%
Cohort Study
11%
Biological Marker
11%
Adalimumab
11%
Randomized Controlled Trial
10%
Tofacitinib
8%
Rectum Hemorrhage
7%
Tumor Necrosis Factor Inhibitor
7%
Calgranulin
6%
Pharmacokinetics
5%
Immunosuppressive Agent
5%
Disease Duration
5%
Aminosalicylic Acid
5%